Clinico-pathological features of relapsing very thin melanoma
L. A. Fearfield, A. Rowe, N. Francis,
C. Fisher, M. E. Gore, C. B. Bunker,
N. Francis
Histopathology, Imperial College School of Medicine (START Laboratory), Chelsea and Westminster and Charing Cross Hospitals, and Departments of
Search for more papers by this authorL. A. Fearfield, A. Rowe, N. Francis,
C. Fisher, M. E. Gore, C. B. Bunker,
N. Francis
Histopathology, Imperial College School of Medicine (START Laboratory), Chelsea and Westminster and Charing Cross Hospitals, and Departments of
Search for more papers by this author
: L. Fearfield, Dermatology Department, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK. Tel.: +44 208 7468173. Fax: +44 208 7468887.E-mail: [email protected]
Abstract
In the UK the incidence of malignant melanoma is increasing and more patients with thinner primary lesions are diagnosed earlier. Most patients with very thin melanoma (< 0.76 mm Breslow thickness) are cured by surgical excision, however, 2–18% relapse over 0–11 years with local or distant metastatic disease and may die. There are still no recognized prognostic or predictive, clinical, serological or molecular markers that accurately determine which of these very thin melanoma will relapse: the Breslow thickness remains the single most important prognostic factor for melanoma in general. Improved prognostic indicators are therefore needed for this rare, but important, unusually aggressive group, to better direct new invasive and expensive investigations and treatment. This article reviews the clinical and histological aspects of relapsing very thin melanoma and discusses the findings of several recent studies, including our own. There is no clinical or biological evidence to support either wide surgical excision or sentinel node biopsy in these patients.
References
- 1 Mackie RM. Melanoma prevention and early detection. Br Med Bull 1995; 51: 570–83.
- 2 Dennis LK. Analysis of the melanoma epidemic, both apparent and real. Arch Dermatol 1999; 135: 275–80.
- 3 Horn-Ross PL, Holly EA, Brown SR, Aston DA. Temporal trends in the incidence of cutaneous malignant melanoma among Caucasians in the San Franscisco–Oakland MSA. Cancer Causes Control 1991; 2: 299–305.
- 4 Thorn M, Ponten F, Bergstrom R et al. Trends in tumour characteristics and survival of malignant melanoma 1960–84: a population-based study in Sweden. Br J Cancer 1994; 70: 743–8.
- 5 Richard MA, Grob JJ, Avril MF et al. Melanoma and tumour thickness; challenges of early diagnosis. Arch Dermatol 1999; 135: 269–74.
- 6 Clark WH, Jr, Elder DE, Guerry Dp IV et al. Model predicting survival in stage I melanoma based on tumour progression. J Natl Cancer Inst 1989; 81: 1893–904.
- 7 Slingluff CL, Vollmer RT, Reintgen DS, Seigler HF. Lethal ‘thin’ malignant melanoma. Ann Surg 1988; 208: 150–61.
- 8
Naruns PL,
Nizze JA,
Cochran AJ et al.
Recurrence potential of thin primary melanomas.
Cancer
1986; 57: 545–8.
10.1002/1097-0142(19860201)57:3<545::AID-CNCR2820570323>3.0.CO;2-K CAS PubMed Web of Science® Google Scholar
- 9 Vilmer C, Bailly C, Le Doussal V et al. Thin melanomas with unusual aggressive behavior: a report of nine cases. J Am Acad Dermatol 1996; 34: 439–44.
- 10 McCarthy WH, Shaw HM, McCarthy SW et al. Cutaneous melanomas that defy conventional prognostic indicators. Semin Oncol 1996; 23: 709–13.
- 11 Moloney DM, Gordon DJ, Briggs JC, Rigby HS. Recurrence of thin melanoma: how effective is follow-up? Br J Plast Surg 1996; 49: 409–13.
- 12 Mehnert JH & Heard JL. Staging of malignant melanoma by depth of invasion: a proposed index of prognosis. Am J Surg 1965; 110: 168–76.
- 13 Clark WH, Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res 1969; 29: 705–26.
- 14 Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902–8.
- 15 Balch CM, Soong S-J, Murad TM et al. A multifactorial analysis of melanoma, II. prognostic factors in patients with stage 1 (localized) melanoma. Surgery 1979; 86: 343–51.
- 16
Balch CM,
Buzaid Ac,
Atkins MB et al.
A new American Joint Committee on Cancer Staging system for Cutaneous Melanoma.
Cancer
2000; 88: 1484–91.
10.1002/(SICI)1097-0142(20000315)88:6<1484::AID-CNCR29>3.0.CO;2-D CAS PubMed Web of Science® Google Scholar
- 17 Slominski A, Ross J, Mihm MC. Cutaneous melanoma: pathology, relevant prognostic indicators and profession. Br Med Bull 1995; 51: 548–69.
- 18 Cook MG, Clarke TJ, Humphreys S et al. The evaluation of diagnostic and prognostic criteria and the terminology of thin cutaneous melanoma by the CRC Melanoma Pathology panel. Histopathology 1996; 28: 497–512.
- 19 Thorn M, Ponten F, Bergstrom R et al. Clinical and histopathological predictors of survival in patients with malignant melanoma – a population based study in Sweden. J Natl Cancer Inst 1994; 86: 761–9.
- 20 Park KGM, Blessing K, McLaren KM, Watson ACH. A study of thin (< 1.5mm) malignant melanomas with poor prognosis. Br J Plast Surg 1993; 46: 607–10.
- 21 Fearfield LA, Rowe A, Fisher C et al. Thin melanomas with unusual aggressive behaviour. Br J Dermatol 1999; 141 (Suppl. 55): 59–60.
- 22 Crowley NJ & Seigler HF. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg 1990; 212: 173–7.
- 23 Tahery DP & Moy RL. Recurrent malignant melanoma following a 35-year disease-free interval. J Dermatol Surg Oncol 1993; 19: 161–3.
- 24
Tsao H,
Cosimi AB,
Sober AJ.
Ultra-late recurrence (15 years or longer) of cutaneous melanoma.
Cancer
1997; 79: 2361–70.DOI: 10.1002/(SICI)1097-0142(19970615)79:12<2361::AID-CNCR10>3.3.CO;2-7
10.1002/(SICI)1097-0142(19970615)79:12<2361::AID-CNCR10>3.0.CO;2-P CAS PubMed Web of Science® Google Scholar
- 25 Bono A, Bartoli C, Clemente C et al. Ambulatory narrow excision for thin melanoma (≤ 2mm): results of a prospective study. Eur J Cancer 1997; 33: 1330–2.DOI: 10.1016/S0959-8049(97)00055-5
- 26 Zitelli JA, Brown CD, Hanusa BH. Surgical margins for excision of primary cutaneous melanoma. J Am Acad Dermatol 1997; 37: 422–9.
- 27 Beasley K & Cartotto RC. Narrow resection of cutaneous melanoma. J Cutan Med Surg 1998; 2: 133–7.
- 28 Veronesi U & Cascinelli N. Narrow excision (1 cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126: 438–41.
- 29 Balch CM, Urist MM, Karakousis CP et al. Efficacy of 2 cm surgical margins for intermediate-thickness melanomas (1–4 mm): results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218: 262–7.
- 30 Heenan PJ & Ghaznawie M. The pathogenesis of local recurrence of melanoma at the primary excision site. Br J Plast Surg 1999; 52: 209–13.
- 31 Griffiths RW & Briggs JC. Incidence of locally metastatic (‘recurrent’) cutaneous malignant melanoma following conventional wide margin excisional surgery for invasive clinical stage 1 tumours: importance of maximal primary tumour thickness. Br J Surg 1986; 73: 349–53.
- 32 Gershenwald JE, Thompson W, Mansfield PF et al. Multi-institutional melanoma lymphatic mapping experience and prognostic value of sentinel lymph node status in 612 stage I and II melanoma patients. J Clin Oncol 1999; 17: 976–83.
- 33 Otley CC & Zitelli JA. Review of sentinel lymph node biopsy and systemic interferon melanoma: promising but investigational modalities. Dermatol Surg 2000; 26: 177–80.
- 34 Wagner JD, Corbett L, Park HM, et al. Sentinel lymph node biopsy for melanoma: experience with consecutive procedures. Plastic Reconstr Surg 2000; 105: 1956–66.
- 35 Bedrosian I, Faries MB, Guerry D IV et al. Incidence of sentinel node metastasis with thin primary melanoma (≤ 1mm) with vertical growth phase. Ann Surg Oncol 2000; 7: 262–7.
- 36 Landi G, Polverelli M, Moscatellli G et al. Sentinel node biopsy in patients with primary cutaneous melanoma: study of 455 cases. J Eur Acad Dermatol Venereol 2000; 14: 35–45.
- 37 Blaheta HJ, Ellwanger U, Schittek B et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 2000; 114: 637–42.
- 38 Bostick PJ, Morton DL, Turner RR et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early stage melanoma patients. J Clin Oncol 1999; 17: 3238–44.
- 39 Lukowsky A, Bellmann B, Ringk A et al. Detection of melanoma micrometastases in the sentinel lymph node and in nonsentinel nodes by tyrosinase polymerase chain reaction. J Invest Dermatol 1999; 113: 554–9.DOI: 10.1046/j.1523-1747.1999.00719.x
- 40 Gadd MA, Cosimi B, Yu J et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg 1999; 134: 381–7.
- 41
Yu LL,
Flotte TJ,
Tanabe KK et al.
Detection of microscopic melanoma metastases in sentinel lymph nodes.
Cancer
1999; 86: 617–27.
10.1002/(SICI)1097-0142(19990815)86:4<617::AID-CNCR10>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 42 Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology 1992; 20: 315–22.
- 43
Trau H,
Rigel DS,
Harris MN et al.
Metastases of thin melanomas.
Cancer
1983; 51: 553–6.
10.1002/1097-0142(19830201)51:3<553::AID-CNCR2820510332>3.0.CO;2-T CAS PubMed Web of Science® Google Scholar
- 44 McGovern VJ, Shaw HM, Milton GW. Prognosis in patients with thin malignant melanomas: influence of regression. Histopathology 1983; 7: 673–80.
- 45 McGovern VJ. Spontaneous regression of melanoma. Pathology 1975; 7: 91–9.
- 46 Ronan SG, Eng AM, Briele HA et al. Thin malignant melanomas with regression and metastases. Arch Dermatol 1987; 123: 1326–30.
- 47 Clark WH & Elder De, van Horn M. The biological forms of malignant melanoma. Hum Pathol 1986; 17: 443–50.
- 48 Guerry IV DP, Synnestvedt M, Elder DE, Schultz. Lessons from tumour progression: The invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 1993; 100: 342S–345S.
- 49 Shellman YG, Chapman JT, Fujita M, Norris Da, Maxwell IH. Expression of activated N-ras in primary melanoma cell line counteracts growth inhibition by transforming growth factor-β. J Invest Dermatol 2000; 114: 1200–4.DOI: 10.1046/j.1523-1747.2000.00988.x
- 50 Degen WG, Van Kempen LC, Gijzen EG et al. MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte adhesion molecule). Am J Pathol 1998; 152: 805–13.
- 51 Van Kempen LC, Van Den Oord JJ, Van Muijen GN et al. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 2000; 156: 769–74.
- 52 Natali PG, Nicotra MR, Bartolazzi A, Cavaliere R, Bigotti A. Integrin expression in cutaneous malignant melanoma: association of the α3/β1 heterodimer with tumor progression. Int J Cancer 1993; 22: 68–72.
- 53
Mansson-Brahme E,
Carstensen J,
Erhardt K et al.
Prognostic factors in thin cutaneous malignant melanoma.
Cancer
1994; 73: 2324–32.
10.1002/1097-0142(19940501)73:9<2324::AID-CNCR2820730914>3.0.CO;2-5 CAS PubMed Web of Science® Google Scholar
- 54 Mackie RM. Malignant melanoma: clinical variants and prognostic indicators. Clin Exp Dermatol 2000; 25: 471–5.
- 55
Massi D,
Franchi A,
Borgognoni L et al. Thin cutaneous malignant melanomas (≤ 1.5mm): identification of risk factors indicative of progression.
Cancer
1999; 85: 1067–76.
10.1002/(SICI)1097-0142(19990301)85:5<1067::AID-CNCR9>3.0.CO;2-T CAS PubMed Web of Science® Google Scholar
- 56 Kelly J, Sagebiel RW, Clyman S, Blois MS. Thin level IV malignant melanoma. Ann Surg 1985; 202: 98–103.
- 57 Margolis DJ, Halpern AC, Rebbeck T et al. Validation of a melanoma prognostic model. Arch Dermatol 1998; 134: 1597–601.
